Trial Profile
Phase I trial of F 652 as a potential therapy for acute pancreatitis.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2021
Price :
$35
*
At a glance
- Drugs F 652 (Primary)
- Indications Pancreatitis
- Focus Adverse reactions
- Sponsors Evive Biotech
- 06 May 2015 New trial record
- 04 May 2015 Generon (Shanghai) Corporation has filed an IND application in China for F 652 to treat acute pancreatitis, according to a media release.